Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carboxylated zinc phthalocyanine is a water-soluble, macrocyclic metallophthalocyanine compound with near-infrared optical properties being investigated as a therapeutic agent for Alzheimer's disease. Developed by researchers at Shimane University, the compound acts as an amyloid-beta (Aβ) aggregation inhibitor. It physically binds to Aβ peptides, decreasing their hydrophobicity and destabilizing pre-formed fibrils, which prevents the formation of neurotoxic oligomers and fibrils. In preclinical mouse models of Alzheimer's disease, treatment with carboxylated zinc phthalocyanine significantly reduced brain amyloid-beta deposition, decreased glial activation (astrocytes and microglia), increased vessel density, and improved cognitive performance without showing liver or kidney toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxylated zinc phthalocyanine.